NextGen cell-based immunotherapies in cancer and other immune disorders

Curr Opin Immunol. 2019 Aug;59:79-87. doi: 10.1016/j.coi.2019.03.007. Epub 2019 May 6.

Abstract

T lymphocyte and other cell therapies have the potential to transform how we treat cancers and other diseases that have few therapeutic options. Here, we review the current progress in engineered T cell therapies and look to the future of what will establish cell therapy as the next pillar of medicine. The tools of synthetic biology along with fundamental knowledge in cell biology and immunology have enabled the development of approaches to engineer cells with enhanced capacity to recognize and treat disease safely and effectively. This along with new modes of engineering cells with CRISPR and strategies to make universal 'off-the-shelf' cell therapies will provide more rapid, flexible, and cheaper translation to the clinic.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Autoimmunity
  • Bioengineering
  • Cancer Vaccines / immunology*
  • Clustered Regularly Interspaced Short Palindromic Repeats
  • Humans
  • Immune System Diseases / immunology
  • Immune System Diseases / therapy*
  • Immunotherapy, Adoptive / methods*
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / transplantation

Substances

  • Cancer Vaccines